Form 4: LAVA Therapeutics Director Exits Options for Cash, CVRs

LAVA Therapeutics Director Peter A. Kiener cancelled 33,390 share options, exchanging them for cash and contingent value rights as part of a pre-arranged plan.

Summary

• Director Peter A. Kiener, a director of LAVA Therapeutics NV, reported the cancellation of 33,390 share options.
• The options had an exercise price of $0.93 per share and were set to expire on February 12, 2035.
• The cancellation was executed on November 13, 2025, under a Purchase Agreement dated August 3, 2025, with XOMA Royalty Corporation.
• In exchange, Kiener received cash and Contingent Value Rights (CVRs).
• The cash component was calculated as the excess of $1.04 over the $0.93 exercise price per share, multiplied by the 33,390 shares, totaling $3,672.90 (net of taxes/deductions).
• Kiener also received one CVR for each of the 33,390 shares underlying the option.
• Following this transaction, Kiener beneficially owns 0 derivative securities.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.
• Kiener is no longer subject to Section 16 reporting obligations.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (option cancellation) under a pre-arranged plan, which is neutral in sentiment for the company. It provides liquidity to the director and is part of a known agreement.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged and systematic approach to trading.
• The director received cash and CVRs for in-the-money options, providing liquidity and potential future value.

Negatives

• The director no longer holds derivative securities in the company, potentially reducing direct alignment with future stock price appreciation from these specific options.

Future Outlook

N/A

Industry Context

This is a routine insider transaction report for a director of a biotechnology company. Such transactions are common and typically reflect individual financial planning rather than broader industry trends, unless they are part of a larger corporate restructuring or acquisition, which is hinted at by the 'Purchase Agreement' with XOMA Royalty Corporation.

Related Party Transactions

• The cancellation of share options by Director Peter A. Kiener, and the exchange for cash and CVRs, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Minimal direct impact from this single director's transaction, as it's a planned disposition. The underlying Purchase Agreement with XOMA Royalty Corporation might have broader implications, but this filing only details the option cancellation.
• Employees/Customers/Suppliers/Creditors: No direct impact from this specific Form 4 filing.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned insider transaction by a director, involving the cancellation of options for cash and CVRs. It does not provide new fundamental information about the company's operations, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is a personal financial event for the director, executed under a known agreement, and is unlikely to significantly impact the company's share price or long-term outlook. Therefore, a 'hold' recommendation is appropriate as there's no new information to alter an existing investment thesis.

Keywords

LAVA Therapeutics, LVTX, Form 4, Insider Trading, Stock Options, Director Transaction, Contingent Value Rights, CVRs, XOMA Royalty Corporation, Peter A. Kiener